Health Technology · Pharmaceuticals: Major · NSE: SUPRIYA · data 2026-10-09
Supriya Lifescience Limited
Health check: Strong (7.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹847.65
Market cap
₹6,939 cr
P/E
34.4
P/B
—
ROE
19.1%
ROCE
22.3%
Debt / equity
0
Dividend yield
0.12%
1-year return
18.5%
52-week high
₹1,085
52-week low
₹545.5
Operating margin
29.7%
Growth
| Revenue (last 12 months) | ₹873 cr |
| Net profit (last 12 months) | ₹198 cr |
| Sales growth, 3 years (yearly) | 21.2% |
| Profit growth, 3 years (yearly) | 32.5% |
Similar companies
Morepen Laboratories Limited (MOREPENLAB) · Bliss GVS Pharma Limited (BLISSGVS) · Symbiotec Pharmalab Limited (SYMBIOTEC) · Sanofi India Limited (SANOFI) · Innova Captab Limited (INNOVACAP)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUPRIYA in NSE Scanner →